Response to Letter. "Romosozumab and cardiovascular safety- should we learn lessons from Pioglitazone?." Tominaga A, Wada K, Okazaki K, Nishi H, et al. Osteoporos Int 2022;33:1401-1402.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tominaga A, Wada K, Okazaki K, Nishi H, et al. Response to Letter. "Romosozumab and cardiovascular safety- should we learn lessons from Pioglitazone?." Osteoporos Int 2022;33:1401-1402.
PMID: 35181822